Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pemafibrate effects on glucose metabolism in hypertriglyceridemia with borderline or early diabetes
jRCTs031190139Completed
- Sponsor
- Kowa Company, Ltd.
- Start
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of pemafibrate in hypertriglyceridemia, type 2 diabetes mellitus (T2DM) and prediabetes (2 arms), sponsored by Kowa Company, Ltd. Primary endpoint: Primary: Change in blood glucose AUC0–2h (75 g OGTT) from baseline to 12 weeks. Started Dec 2021; status: completed.
02
Drugs
pemafibrate
03
Conditions
hypertriglyceridemiatype 2 diabetes mellitus (T2DM)prediabetes
Beyond the preview
Go deeper on jRCTs031190139.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031190139.